Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 1 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 167 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 25 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 167 Underlying: Common Stock · 167 shares Expires 2026-06-25 F27 · price: Received in exchange for a warrant to purchase 5,775 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 113 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 24 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 113 Underlying: Common Stock · 113 shares Expires 2026-03-04 F26 · price: Received in exchange for a warrant to purchase 3,915 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 840 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 23 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 840 Underlying: Common Stock · 840 shares Expires 2026-06-25 F25 · price: Received in exchange for a warrant to purchase 29,139 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 569 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 22 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 569 Underlying: Common Stock · 569 shares Expires 2026-03-04 F24 · price: Received in exchange for a warrant to purchase 19,754 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 3,249 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 21 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), LP Disclosed balance after: 3,249 Underlying: Common Stock · 3,249 shares Expires 2026-06-25 F23 · price: Received in exchange for a warrant to purchase 112,796 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 2,203 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 20 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), LP Disclosed balance after: 2,203 Underlying: Common Stock · 2,203 shares Expires 2026-03-04 F22 · price: Received in exchange for a warrant to purchase 76,470 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 12,380 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 19 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, LP Disclosed balance after: 12,380 Underlying: Common Stock · 12,380 shares Expires 2026-06-25 F21 · price: Received in exchange for a warrant to purchase 429,837 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 8,393 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 18 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, LP Disclosed balance after: 8,393 Underlying: Common Stock · 8,393 shares Expires 2026-02-22 F20 · price: Received in exchange for a warrant to purchase 291,407 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 183 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 17 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 183 Underlying: Common Stock · 183 shares Expires 2026-06-25 F19 · price: Received in exchange for a warrant to purchase 6,343 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 237 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 16 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 237 Underlying: Common Stock · 237 shares Expires 2026-03-04 F18 · price: Received in exchange for a warrant to purchase 8,203 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 15,403 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 15 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 15,403 Underlying: Common Stock · 15,403 shares Expires 2026-06-25 F17 · price: Received in exchange for a warrant to purchase 534,815 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 6,852 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 14 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 6,852 Underlying: Common Stock · 6,852 shares Expires 2026-02-22 F16 · price: Received in exchange for a warrant to purchase 237,911 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 1,910 | Not disclosed Strike: $26.74 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 13 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 1,910 Underlying: Common Stock · 1,910 shares Expires 2027-02-28 F15 · price: Received in exchange for a warrant to purchase 66,305 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 2,685 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 12 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,685 Underlying: Common Stock · 2,685 shares Expires 2026-06-25 F14 · price: Received in exchange for a warrant to purchase 93,225 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 16,539 | Not disclosed Strike: $27.94 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 11 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,539 Underlying: Common Stock · 16,539 shares Expires 2026-02-22 F13 · price: Received in exchange for a warrant to purchase 574,269 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantWarrant · Derivative | 2,672 | Not disclosed Strike: $26.74 | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · derivative · entry 10 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,672 Underlying: Common Stock · 2,672 shares Expires 2027-02-28 F12 · price: Received in exchange for a warrant to purchase 92,748 shares of common stock of CalciMedica pursuant to the Merger Agreement. F11 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 1,548 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 9 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VII Disclosed balance after: 1,548 F10 · price: Received in exchange for 53,733 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 63,228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 8 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P. Disclosed balance after: 63,228 F8 · price: Received in exchange for 2,195,354 shares of the common stock of CalciMedica pursuant to the Merger Agreement. F9 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 14,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 7 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P. Disclosed balance after: 14,425 F7 · price: Received in exchange for 500,854 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 240,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 6 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures VII, L.P. Disclosed balance after: 240,676 F6 · price: Received in exchange for 8,356,779 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 8,884 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 5 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling VI Limited Partnership Disclosed balance after: 8,884 F5 · price: Received in exchange for 308,455 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 7,456 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 4 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling VI Beteligungs GmbH & Co KG Disclosed balance after: 7,456 F4 · price: Received in exchange for 258,883 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 17,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 3 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Ventures Management VI Disclosed balance after: 17,682 F3 · price: Received in exchange for 613,943 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 582,757 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 2 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P. Disclosed balance after: 582,757 F2 · price: Received in exchange for 20,234,606 shares of the common stock of CalciMedica pursuant to the Merger Agreement. Read SEC document |
| March 20, 2023 Filed Oct 10, 2023 16:15 UTC |
Sanderling Venture Partners VI LP10% owner
Sanderling Ventures Management VI10% owner
Sanderling VI Limited Partnership10% owner
Sanderling Ventures VII, L.P.10% owner
Sanderling Ventures Management VII10% owner
|
GrantCommon Stock | 703,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052521 · doc4.xml · nonDerivative · entry 1 Sanderling Venture Partners VI LP · CIK 0001306717 · 10% owner Sanderling Venture Partners VI Co Investment Fund LP · CIK 0001306695 · 10% owner Sanderling Ventures Management VI · CIK 0001429588 · 10% owner Sanderling VI Beteiligungs GmbH & Co KG · CIK 0001429283 · 10% owner Sanderling VI Limited Partnership · CIK 0001429282 · 10% owner Sanderling Ventures VII, L.P. · CIK 0001565862 · 10% owner Sanderling Ventures VII Annex Fund, L.P. · CIK 0001678656 · 10% owner Sanderling Ventures Management VII · CIK 0001993457 · 10% owner Sanderling Ventures VII (Canada), L.P. · CIK 0001993660 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 703,388 F1 · price: Received in exchange for 24,423,158 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 16:15 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018885 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on September 4, 2021, and 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 16:15 UTC |
BREUIL ROBERT SChief Financial Officer
|
Tax withholdingCommon Stock | 1,730 | $0.58 | $1,003.40 |
DisclosureSEC source: 0001209191-23-018885 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,119 Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 16:15 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018885 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 18:59 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016509 · doc4.xml · derivative · entry 5 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,750 Underlying: Common Stock · 28,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 18:59 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 83,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016509 · doc4.xml · derivative · entry 4 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vested as to 100% of the total RSUs on February 28, 2023 and settled on March 3, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 18:59 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016509 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,438 Underlying: Common Stock · 9,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 18:59 UTC |
BREUIL ROBERT SChief Financial Officer
|
Tax withholdingCommon Stock | 49,434 | $0.57 | $28,177.38 |
DisclosureSEC source: 0001209191-23-016509 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,849 Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 18:59 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionCommon Stock | 121,217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016509 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC |
Zamiri ParisaChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · derivative · entry 5 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,750 Underlying: Common Stock · 28,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC |
Zamiri ParisaChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 83,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · derivative · entry 4 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vested as to 100% of the total RSUs on February 28, 2023 and settled on March 3, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC |
Zamiri ParisaChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · derivative · entry 3 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,375 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC |
Zamiri ParisaChief Medical Officer
|
Tax withholdingCommon Stock | 42,894 | $0.57 | $24,449.58 |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · nonDerivative · entry 2 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,338 Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:04 UTC |
Zamiri ParisaChief Medical Officer
|
Exercise / conversionCommon Stock | 120,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016514 · doc4.xml · nonDerivative · entry 1 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:02 UTC |
Guerard FredericDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 65,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016513 · doc4.xml · derivative · entry 5 Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,750 Underlying: Common Stock · 65,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:02 UTC |
Guerard FredericDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 221,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016513 · doc4.xml · derivative · entry 4 Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 221,746 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vested as to 100% of the total RSUs on February 28, 2023 and settled on March 3, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:02 UTC |
Guerard FredericDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016513 · doc4.xml · derivative · entry 3 Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,125 Underlying: Common Stock · 28,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:02 UTC |
Guerard FredericDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 89,344 | $0.57 | $50,926.08 |
DisclosureSEC source: 0001209191-23-016513 · doc4.xml · nonDerivative · entry 2 Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,682 Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 00:02 UTC |
Guerard FredericDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 315,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016513 · doc4.xml · nonDerivative · entry 1 Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:07 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061177 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on September 4, 2021, and 1/12 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on September 4, 2024, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:07 UTC |
BREUIL ROBERT SChief Financial Officer
|
Tax withholdingCommon Stock | 1,729 | $0.58 | $1,002.82 |
DisclosureSEC source: 0001209191-22-061177 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,066 Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:07 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-061177 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 16:50 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059207 · doc4.xml · derivative · entry 3 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,375 Underlying: Common Stock · 9,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 16:50 UTC |
BREUIL ROBERT SChief Financial Officer
|
Tax withholdingCommon Stock | 3,437 | $0.63 | $2,165.31 |
DisclosureSEC source: 0001209191-22-059207 · doc4.xml · nonDerivative · entry 2 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,795 Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 16:50 UTC |
BREUIL ROBERT SChief Financial Officer
|
Exercise / conversionCommon Stock | 9,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-059207 · doc4.xml · nonDerivative · entry 1 BREUIL ROBERT S · CIK 0001241009 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 01, 2022 Filed Dec 1, 2022 21:50 UTC |
Zamiri ParisaChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059206 · doc4.xml · derivative · entry 3 Zamiri Parisa · CIK 0001824806 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.